Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 13/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | ADA | P00813 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133659 | 0.90 | ACLY (0.41) | ACLYPTGER1KDM5AKDM2BKDM4C | |
| SCHEMBL6170939 | 0.89 | ADA (0.45) | ACLYPTGER1ADALPAR1 | |
| Hydrochloric Acid SCHEMBL6134584 | 0.89 | SLC1A5 (0.42) | ACLYPTGER1ADA | |
| SCHEMBL6133619 | 0.85 | ACLY (0.45) | ACLYPTGER1KDM5AKDM2BKDM4C | |
| SCHEMBL6133373 | 0.84 | ACLY (0.36) | ACLYPTGER1ADA | |
| SCHEMBL6133437 | 0.84 | PTGER1 (0.42) | PTGER1ADA | |
| SCHEMBL6134089 | 0.83 | CARM1 (0.39) | ACLYPTGER1ADALPAR1 | |
| SCHEMBL6133845 | 0.83 | ADA (0.41) | PTGER1ADALPAR1 | |
| SCHEMBL6133407 | 0.82 | PTGER1 (0.41) | PTGER1ADA | |
| SCHEMBL6134115 | 0.82 | PTGER1 (0.39) | ACLYPTGER1ADALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | claimed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ACLY 1604/4885PTGER1 1527/4885KDM5A 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.